<sup>18</sup>F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging

McConathy, Jonathan

doi:10.2967/jnumed.116.175489

Cited by 16 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer can occur synchronously in patients with recurrent prostate cancer; however, they have different degrees of 18 F-fluciclovine uptake (38). Breast cancers demonstrate significantly increased 18 Ffluciclovine uptake compared with benign lesions such as scarring after therapy, fibroadipose tissue, and fibrocystic change (39,40). Aggressive breast cancers may demonstrate relatively increased uptake and histologic subtypes such as invasive lobular carcinoma may demonstrate increased uptake with 18 F-fluciclovine as compared with 18 F-FDG (39).…”

Section: F-fluciclovine Imagingmentioning

confidence: 99%

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Rahman

Neal

Nees

et al. 2020

Radiology: Imaging Cancer

View full text Add to dashboard Cite

N uclear medicine studies such as bone scan, lymphoscintigraphy, and fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) PET/CT may be performed in patients with breast cancer for staging and treatment planning. Focal or diffuse radiotracer uptake can also be incidentally found within the breast in patients without breast cancer. These findings may be clinically relevant and could correlate with mammogram or breast US to help confirm a suspected diagnosis, which may save the patient additional workup and anxiety. Certain lesions may demonstrate avid uptake of one radiotracer but fail to have any uptake of another. Familiarity with the expected level of radiotracer uptake of specific breast lesions may also aid in making the correct diagnosis. There are PET radiotracers including gallium 68 ( 68 Ga) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE), 18 F-fluciclovine, and 68 Ga-prostate-specific membrane antigen (PSMA) that may also demonstrate incidental breast uptake. Reviewing pathologic correlation of these incidental lesions can be helpful in future imaging interpretation.The goals of this review are to demonstrate the spectrum of breast lesions that can be detected on various molecular imaging studies, present relevant features on correlative anatomic imaging, and help the reader obtain additional imaging when warranted. This institutional review boardapproved, Health Insurance Portability and Accountability Act-compliant pictorial essay will provide an overview of various planar, SPECT, and PET nuclear medicine studies and the breast lesions that can be detected at each.

show abstract

Section: F-fluciclovine Imagingmentioning

confidence: 99%

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Rahman

Neal

Nees

et al. 2020

Radiology: Imaging Cancer

View full text Add to dashboard Cite

show abstract

“…18F‐Fluciclovine uptake in nonprostate cancer cells has been reported most commonly in the setting of primary breast and gastrointestinal malignancies 3 . 18F‐Fluciclovine has shown promise as a potential imaging tool for breast malignancy 4 . Small pilot studies have shown significantly higher 18F‐fluciclovine uptake in malignant breast lesions including invasive lobular breast cancer and invasive ductal breast cancer in comparison with benign lesions.…”

Section: Introductionmentioning

confidence: 99%

Atypical gynecomastia mimicking breast malignancy on mammography, sonography, and 18F‐fluciclovine PET/CT in the setting of biochemical recurrence of prostate cancer

2020

View full text Add to dashboard Cite

A 60-year-old man with metastatic prostate cancer presented with breast swelling for one year. Suspicious breast masses were identified in both breasts with mammography and ultrasound. Biopsy of both masses showed florid gynecomastia without How to cite this article: Winter AM, Osman M, Bennett DL. Atypical gynecomastia mimicking breast malignancy on mammography, sonography, and 18F-fluciclovine PET/CT in the setting of biochemical recurrence of prostate cancer.

show abstract

“…Recent studies [ 83 – 85 ] have shown that 18 F-fluciclovine that is a leucine analog radioactive tracer can also be used for breast cancer PET/CT imaging. 18 F-fluciclovine PET/CT visualizes malignant tumors including invasive lobular breast cancer (ILC) and invasive ductal breast cancer (IDC).…”

Section: Introductionmentioning

confidence: 99%

“…18 F-fluciclovine also detected lymph nodes and bone metastases, but liver metastases were less effective due to the high physiological uptake of the tracer in liver parenchyma. The highest uptake of 18 F-fluciclovine appears in Nottingham grade 3 cancers and triple-negative breast cancers, suggesting that 18 F-fluciclovine may play a role in identifying more aggressive malignancies [ 83 – 85 ]. 18 F-FASu may serve as a valuable target for the diagnosis and treatment monitoring of certain breast cancers and may provide more sensitive detection than 18 F-FDG in certain tumors [ 86 , 87 ].…”

Section: Introductionmentioning

confidence: 99%

Fluorine-18 labeled amino acids for tumor PET/CT imaging

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Tumor glucose metabolism and amino acid metabolism are usually enhanced, 18F-FDG for tumor glucose metabolism PET imaging has been clinically well known, but tumor amino acid metabolism PET imaging is not clinically familiar. Radiolabeled amino acids (AAs) are an important class of PET/CT tracers that target the upregulated amino acid transporters to show elevated amino acid metabolism in tumor cells. Radiolabeled amino acids were observed to have high uptake in tumor cells but low in normal tissues and inflammatory tissues. The radionuclides used in labeling amino acids include 15O, 13N, 11C, 123I, 18F and 68Ga, among which the most commonly used is 18F [1]. Available data support the use of certain 18F-labeled AAs for PET/CT imaging of gliomas, neuroendocrine tumors, prostate cancer and breast cancer [2, 3]. With the progress of the method of 18F labeling AAs [4–6], 18F-labeled AAs are well established for tumor PET/CT imaging. This review focuses on the current status of key clinical applications of 18F-labeled AAs in tumor PET/CT imaging.

show abstract

¹⁸F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging

Cited by 16 publications

References 12 publications

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Atypical gynecomastia mimicking breast malignancy on mammography, sonography, and 18F‐fluciclovine PET/CT in the setting of biochemical recurrence of prostate cancer

Fluorine-18 labeled amino acids for tumor PET/CT imaging

Contact Info

Product

Resources

About

18F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging

Cited by 16 publications

References 12 publications

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Atypical gynecomastia mimicking breast malignancy on mammography, sonography, and 18F‐fluciclovine PET/CT in the setting of biochemical recurrence of prostate cancer

Fluorine-18 labeled amino acids for tumor PET/CT imaging

Contact Info

Product

Resources

About

¹⁸F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging